|Animas® OneTouch® Ping®||Animas® Vibe™||MiniMed™ 630G system||MiniMed™ 670G system|
|Medtronic MiniMed™ Pump Features|
|Automated basal (background) insulin delivery based on CGM readings to maximize time in range*,#|
|Ability to suspend insulin before lows occur§|
|Ability to suspend insulin when lows occur§|
|Shared Pump Features|
|Built-in continuous glucose monitoring (CGM) that communicates with the pump||
|Ability to give an insulin bolus from a wireless meter|
|Bright color screen|
|Animas® Pump Features|
|Smaller, 200 units reservoir|
|CalorieKing® Food Database|
The MiniMed™ 670G system offers SmartGuard™ technology with two new levels of automated insulin delivery — the Auto Mode and Suspend before low features.
SmartGuard™ Auto Mode‡
SmartGuard™ Suspend before low§
If your pump warranty has already expired or is set to expire soon, you’re at risk of going off therapy should something happen to your Animas® pump.
∆Restrictions apply. Programs available to qualified customers with a valid prescription. Cost may vary based on warranty status, program eligibility and insurance coverage. Program terms and conditions are subject to change at any time and without notice.
We get it, you have a lot to think about when considering a transition between your next pump, CGM, and extra supplies. We want to make your transition to Medtronic as seamless as possible. For a limited time, Medtronic will swap out your Animas® pump supplies for Medtronic supplies.∆
While you consider your options, we also want to make sure you have discussed back-up options with your physician and received answers to any questions you may have. Animas® has arranged for in-warranty customers to transition to a Medtronic pump at no cost. Note: you must be in-warranty 60 days beyond the date you enroll. Call 855-322-9568 option 2 to learn more.
If your Animas® pump is out of warranty or will be out of warranty in the next two months, you may benefit from the Lift Ticket. Call 855-322-9568 option 1 to learn more.
Customers who choose not to transition to a Medtronic pump and continue to use their Animas® pump should be aware that effective September 30, 2019, Medtronic will no longer be able to supply Animas® cartridges or customer support for Animas® pumps, so you may want to consider alternative therapy options.
For information on Animas® warranty policy visit www.animas.com
Whether you’re an Animas® Vibe® or Animas® Ping® customer, rest assured you can now order your infusion sets, cartridges, and other supplies directly through the Medtronic Store.
Finding your diabetes-related supplies and accessories just got easier thanks to the all-new Diabetes.Shop. Check it out today!
Animas® decided to close their insulin pump business in the U.S. and Canada in October 2017. Animas® selected Medtronic as the partner of choice to provide customer support to Animas® customers while they transition to new pump options through September 30th, 2019.
Our first priority is to ensure there is no therapy disruption for Animas® customers given the significant benefits insulin pump therapy provides. As such, Medtronic has stepped up to provide support to Animas® customers by offering supplies and support along with offering pump transition programs inclusive of low to no cost options for eligible customers.
Medtronic was selected because of our rich 30-year history of innovation and service. Medtronic has supported over 1.2 million people living with diabetes around the world. Medtronic customers have access to 24-hour technical product support, supply reorder services, and dedicated global customer support. Our unparalleled service is the #1 reason that people with diabetes stay with Medtronic.
Medtronic has taken over the support function for Animas® patients. Supply ordering and support has been transitioned to Medtronic as of January 2018. You can continue to use the same phone numbers to contact customer support for your Animas® pump, 877.937.7867.
This only affects Animas® Vibe® and OneTouch Ping® insulin pumps and related supplies. There is no impact on OneTouch blood glucose meters and related supplies, which you can continue to purchase from your existing supplier.
If you are out of warranty, Animas® will no longer provide service or a replacement for your insulin pump. This means you are at risk of going off therapy and back to multiple daily injections should anything happen to your Animas® pump.
We would like to offer you an alternative option today to replace your Out-of-Warranty Animas® pump and ensure you do not experience a disruption in therapy.
To learn about pump transition programs available through Medtronic, call 855.322.9568.
In-warranty Animas® patients have the option to receive a new MiniMedTM system for the remainder of their Animas® pump warranty period. Animas® has arranged for this transition option to occur at no cost to the patient to ensure continuity of therapy.
Medtronic is now accepting enrollment for this program. The program is only offered for a limited time, and you must have more than 60 days left on your warranty to qualify. To learn more about the program or to enroll, call 855.322.9568 and select option 2.
Customers who choose not to transition to a Medtronic insulin pump under this program can continue to use their Animas insulin pump; however, after September 30, 2019, Medtronic will not be able to supply Animas® supplies and customer support will no longer be provided for Animas pumps by Medtronic. To avoid the risk of going back to multiple daily injections, consider learning about your next pump options now.
We make it easy for our customers to stay connected with us and others in the Diabetes Online Community. Through our social channels, we share helpful diabetes tips, stories and perspectives from the community as well as from our Medtronic team. We count on our robust online community to give us feedback and help shape the solutions we innovate to help transform diabetes care so we invite you to join the conversation and stay connected with us!
1. Bergenstal R, Garg S, Weinzimer S, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316(13):1407–1408.
2. dQ&A. (2017) dQ&A Patient Panel, Q4 2016, Summary Report.
* Refers to SmartGuard™ Auto Mode feature; The MiniMed™ 670G system can automatically increase or decrease insulin delivery based on continuous glucose monitoring (CGM) values; however, the user must still administer meal boluses. ADA recommendation for a glucose range is 80-180 mg/dL in non-pregnant adults with diabetes. Individual results may vary.
# Based on Guardian™ Sensor 3 glucose values.
∆ Restrictions apply. Programs available to qualified customers with a valid prescription. Cost may vary based on warranty status, program eligibility and insurance coverage. Program terms and conditions are subject to change at any time and without notice.
§ WARNING: Do not use the Suspend on low feature to prevent or treat low glucose. Always confirm your sensor glucose reading using your BG meter, and follow the instructions of your healthcare professional to treat low glucose. Using Suspend on low alone to prevent or treat low glucose may result in prolonged hypoglycemia.
† At the time of manufacture and when the reservoir and tubing are properly inserted, your pump is waterproof. It is protected against the effects of being underwater to a depth of up to 12 feet (3.6 meters) for up to 24 hours.
‡ WARNING: Do not use Auto Mode for a period of time after giving a manual injection of insulin by syringe or pen. Manual injections are not accounted for in Auto Mode. Therefore, Auto Mode could deliver too much insulin. Too much insulin may cause hypoglycemia. Consult with your healthcare professional for how long you need to wait after a manual injection of insulin before you resume Auto Mode.
Important Safety Information: MiniMed™ 630G System with SmartGuard™ technology
Indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus. MiniMed™ 630G system is approved for ages 14 years or older with Guardian™ Sensor 3 and MiniMed™ 630G system is approved for ages 16 years or older with Enlite™ sensor. Both systems require a prescription. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. Replace the infusion set every 48–72 hours, or more frequently per your healthcare professional’s instructions. Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick using a CONTOUR®NEXT LINK 2.4 meter is required prior to making adjustments to diabetes therapy. Always check the pump display when using a CONTOUR®NEXT LINK 2.4 meter, to ensure the glucose result shown agrees with the glucose results shown on the meter. Do not calibrate your CGM device or calculate a bolus using a result taken from an Alternative Site (palm) or a result from a control solution test. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. The MiniMed™ 630G or MiniMed™ 530G system are not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the Suspend on low alarm and take measures to prevent or treat hypoglycemia themselves. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare provider.
WARNING: The SmartGuard™ Suspend on low feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set threshold. Under some conditions of use the pump can suspend again, resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard feature, it is important to read the SmartGuard™ feature information in the User Guide and discuss proper use of the feature with your healthcare provider.
Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day.
Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms.
Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected.
Important Safety Information: MiniMed™ 670G System
The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.
The Medtronic MiniMed™ 670G System consists of the following devices: MiniMed™ 670G Insulin Pump, the Guardian™ Link (3) Transmitter, the Guardian™ Sensor (3), One-press Serter, and the CONTOUR® NEXT Link 2.4 Glucose Meter. The system requires a prescription.
The Guardian™ Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian™ Sensor (3).
WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library
Guardian™ Sensor (3) The Guardian™ Sensor (3) is intended for use with the MiniMed™ 670G system to continuously monitor glucose levels in persons with diabetes. It is intended to be used for detecting trends and tracking patterns in persons aged fourteen years and older, and to be used by the MiniMed™ 670G system to automatically adjust basal insulin levels. It is indicated for use as an adjunctive device to complement, not replace, information obtained from standard blood glucose monitoring devices. The sensor is intended for single use and requires a prescription. The Guardian Sensor (3) is indicated for 7 days of continuous use.
The serter is used as an aid for inserting the sensor. It is indicated for single-patient use and is not intended for multiple patient use.
Guardian Link (3) Transmitter
The Guardian™ Link (3) Transmitter is intended for use with MiniMed™ 670G System. The Guardian™ Link (3) Transmitter powers the glucose sensor, collects and calculates sensor data, and wirelessly sends the data to the MiniMed™ 670G insulin pump. The Transmitter is intended for single-patient multi-use.
CONTOUR®NEXT LINK 2.4 Glucose Meter
The CONTOUR®NEXT LINK 2.4 Wireless Blood Glucose Monitoring System is an over the counter (OTC) device utilized by persons with diabetes in home settings for the measurement of glucose in whole blood, and is for single patient use only and should not be shared. The CONTOUR®NEXT LINK 2.4 wireless blood glucose monitoring system is indicated for use with fresh capillary whole blood samples drawn from the fingertip and palm only. The CONTOUR®NEXT Test Strips are intended for self-testing by persons with diabetes for the quantitative measurement of glucose in whole blood samples from 20 to 600 mg/dL. The CONTOUR®NEXT LINK 2.4 wireless blood glucose transmit glucose values to the MiniMed™ 670G insulin pump and facilitate transfer of information to Medtronic CareLink™ Software through the use of radio frequency communication. The CONTOUR®NEXT LINK 2.4 Wireless Blood Glucose Monitoring System is not intended for the diagnosis of, or screening for, diabetes mellitus. It is not intended for use on neonates.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Do not use the serter on products other than the Enlite sensor or Guardian Sensor (3). Medtronic cannot guarantee the safety or efficacy of this product if used with other products. The reservoir is contraindicated for the infusion of blood or blood products. Infusion sets are indicated for subcutaneous use only and not for intravenous (IV) infusion or the infusion of blood or blood products. Insulin pump therapy is not recommended for those who are unwilling to perform at least four blood glucose tests per day. As insulin pumps use rapid acting insulin only, BG testing is required to help identify rapid glycemic deterioration due to insulin infusion occlusion, infusion site problems, insulin stability issues, user error, or a combination of these. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional.
For additional information, please consult the appropriate User Guide.
© Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.